Academics

Dr. Lamiaa Mohsen,
Dean of the School of Medicine

National and international expert who worked with various governmental and international agencies in the field of health care, education, maternal and child welfare and human resource development.

In September 2016, Lamiaa was appointed as the Founding Dean for Faculty of Medicine Newgiza University which was the first School of Medicine in Egypt to implement the modular integrated curriculum and assessment.

Lamiaa is a member of the RUMP (Reform of Undergraduate Medical Program) committee shared among experts in the preparatory steps for the implementation of the new undergraduate medical curriculum that started in September 2019 in all Egyptian Medical schools.

Lamiaa is a member of the Pediatric Medical Council in the Arab Board since 2014. In this position she is responsible for the preparation, participating and evaluating OF postgraduate training and Assessment in all Arab Countries as well as accreditation of hospitals as training sites.

As a Professor of Pediatrics and Neonatology in Cairo University, Lamiaa was involved in undergraduate teaching and research with twelve international publications in the last five years. Lamiaa was appointed as Director for the Center for Social and Preventive Medicine, Cairo University, a body that links medical higher education to the health needs of the community.

Lamiaa worked with USAID and European Union projects in Indonesia, Jordan, Yemen, and Syria in the fields of Health and child protection. Her leadership skills were solidified through attending The International Health Leadership Program in Cambridge and team-leading The National Egyptian Perinatal Program.

She was appointed 2010-2012 as Secretary-General for the National Council for Childhood and Motherhood, the highest authority in Egypt responsible for protection, promotion and monitoring implementation of Child and adolescent rights in Egypt.

Goals  

• Development of educational programs in accordance with national accreditation standards and achieving excellence locally, regionally and internationally. 

• Innovation and excellence with incorporation of ethical principles in scientific research, publications, and postgraduate studies. 

• Adopt Innovation and upgrading of scientific research, scientific publishing and training all while maintaining ethical principles. 

• Enhancement of the institutional capacity building and development of the institutional evaluation systems. 

• Social accountability and enhancement of the community and environmental services offered by the school with a commitment to the amelioration of the health standards of the community, while respecting and appreciating social and cultural Diversity.
   

Strategic Objectives: 

• Prepare the graduates, who are knowledgeable and can apply  skills allowing pursuit of life-long learning, 

• Providing an undergraduate education in accordance with the national, regional and international global academic reference standards , maintains ethical practice, provides graduates prepared for labor market needs, and enhances competitiveness. 

• Continuous development of the educational process, supporting students and alumni throughout their university years and beyond. 

• Providing  an effective educational experience aligned with international standards by fostering academic collaboration with the University College London (UCL) in England.  

• Advancement of scientific research by promotion of innovation and through national and international collaboration.  

• Establishment of distinctive postgraduate studies in all medical fields. 

• Sustainable development of human and physical resources with the latest equipment and technology and in accordance with comprehensive quality standards (faculty, students, education resources: halls, laboratories) to uphold its competitive standing. 

• Enhancing the school’s role in community service and environmental initiatives by forming strategic alliances with organizations in the civic society. 

The SOM MBBCh program aims at producing a distinctive NGU doctor; a scientifically literate, research informed, patient minded and socially responsible professional who can serve the medical needs of individuals and communities both in Egypt and abroad. 

• SOM collaborates with the esteemed institution UCL (University College London). 

• It follows a modular integrated system that adheres to well-established international standards. 

• Provides early clinical exposure. 

• Involves 3 years of clinical undergraduate practice, followed by2 years of clinical internship. 

• Adheres to international standards of teaching and assessment. 

Accreditation: 

Newgiza University (NGU) was established as a private university by a presidential Decree “93” in April 2010. NGU schools are acknowledged by the Ministry of Higher Education (MHE) and the Supreme Council of Universities (SCU).

The university will eventually include twelve Schools: Medicine; Pharmacy; Dentistry; Nursing and Health Science; Economics and Politics; Law; Business and Finance; Engineering; Information Technology; Fine Arts; Archaeology; and Languages and Interpretation. Currently, eight schools are functioning (Medicine, Dentistry, Pharmacy, Business and Finance, Economics and Politics, Engineering, Information Technology, and Fine Arts).

The School of Medicine was acknowledged by decree “3356” in August 2016. Every school will apply for accreditation by the National Authority for Quality Assurance and Accreditation in Education (NAQAAE) after the graduation of the first cohort.

University College London (UCL):

The School of Medicine at NGU has an academic collaboration with University College London (UCL), enhancing its academic capabilities, as well as offering world-renowned undergraduate program, providing both the school and students with ample opportunities for development on an academic and personal level.

This collaboration ensured that the highest international standards in teaching and research are met at NGU, with highly qualified faculty members providing instruction and supervision. As part of this collaboration, senior faculty, and staff from UCL worked with their NGU colleagues in strategic planning and organization of the new programs, setting up appropriate infrastructure and education governance structures, developing curricula and learning resources, faculty and senior staff recruitment, faculty development, course evaluation and education quality assurance. Where appropriate, NGU utilizes existing UCL teaching and assessment resources to deliver its programs.

Having currently ranked 9th on the QS World University Rankings 2024, and consistently placing in the top 20 of various global university rankings, UCL is widely recognized for its research capabilities and contributions to sciences and innovations. It was rated 2nd in the UK for research power in the Research Excellence Framework 2021. Moreover, UCL boasts 30 Nobel Prize winners, and was recently selected as University of the Year 2024 (The Times and Sunday Times Good University Guide 2024).

The UCL Medical School is currently ranked 6th in the world in the QS World University Rankings by Subject (2023).

Fall 2024 Entrance Requirements – School of Medicine

As a student of medicine at NGU you will be joining an exciting and impressive medical school. Your degree will follow a Five-year academic program (followed by  Two-years internship) that includes a stimulating Introductory Module where you will learn alongside students from the other health and life sciences programs followed by a series of ‘horizontal modules’ which focus on body systems and clinical disciplines and vertical themes which focus on important professional topics including clinical skills, professional development, social determinants of health and use of evidence, Student activities and electives.

Your Learning

You will be taught through lectures, tutorials, small-group work, laboratory classes and placements. Later years will involve attachments to teams of consultants and doctors. You will be expected to supplement learning in the university and in healthcare settings with directed self-learning.

You will be assessed by contemporary assessment methods including single best answer questions, objective structured practical examinations and objective structured clinical examinations supplemented with a complete portfolio. The program integrates basic medical sciences and clinical sciences with professional skills and competencies throughout. Small group work and assigned tasks will enhance key generic skills including independent learning, critical thinking, scholarly writing and scientific method.

The MBBCh is five Academic years & two years internship in duration (Eleven semesters). This includes an Introductory Module that is shared with other health education programs at NGU (Dentistry and Pharmacy).

The MBBCh program is an integrated program. This means a deliberate blurring of the boundaries between basic science, and clinical science, between theory and practice and between disciplines. Although delivered in an integrated format, the program includes all the core basic sciences, clinical sciences, practical knowledge and skills and professional and generic skills required to address the intended learning outcomes.

The program contains 308 credit units over 11 semesters. These credit units do not represent only contact hours, but the total learning effort required to achieve the learning outcomes including direct contact hours in classrooms, small groups and practical classes, workplace-based learning in clinical placements, project work, self-paced learning delivered via the Virtual Learning Environment (VLE) and self-directed learning. A credit unit is estimated to represent approximately 25 hours of study.

Year 1 | Introductory Module and fundamentals of clinical science 1

Introductory Module: 8 weeks (13CUs)
Infection and Defence: 5 weeks (10CUs)
Behavioral sciences: 3 weeks (6CUs)
Circulation and Breathing: 8 weeks (14CUs)
Fluids, Nutrition and Metabolism: 8 weeks (13CUs)

Year 2 | Fundamentals of Clinical Science 2, 3 & Fundamentals of Clinical Science Practice

Movement and Musculoskeletal Biology: 8 weeks (13CUs)
Endocrine Systems and Regulation: 7 weeks (13CUs)
Neuroscience and Behaviour: 9 weeks (14CUs)
Development, Genetics, and Cancer: 6 weeks (10CUs)
Foundations of Clinical Practice: 4 weeks (6CUs)

Year 3 | Integrated Clinical Care

Integrated Clinical Care 1, CVS, Respiratory& Acute Care: 12 weeks (22CUs)
Integrated Clinical Care 2, Care of Surgical Patient, Anaesthetics & General Surgery: 12 weeks (21CUs)
Integrated Clinical Care 2; Endocrinology, Haematology, Nephrology & Neurology: 12 weeks (21CUs)

Year 4 | The Life Cycle and Community Medicine

Child Health & Mental Health: 12 Weeks (22CUs)
Women’s Health & Mental Health: 12 Weeks (22CUs)
Family Health, Community Health, Public Health & Mental Health: 12 Weeks (22CUs)

Year 5 | Specialist Practice and Preparation for Practice

Special Senses (Dermatology, ENT & Ophthalmology): 7 Weeks (10CUs)
Oncology and Palliative Care, Care of the Elderly: 6 Weeks (10CUs)
Senior Clerkship (Medicine & Surgery): 18 Weeks (30CUs)
Emergency Care (Including Trauma and orthopaedics): 6 Weeks (10CUs)
Elective Module: 4 Weeks (6CUs)
Preparation for practice: 4 Weeks (8 CUs)

Modules:
Each year contains both horizontal modules (completed within the year) and vertical modules (running through the entire program).
Some elective modules are available to enrich the program and allow students to pursue an area of personal interest or career-related in depth.

The vertical modules:
• Anatomy and Imaging
• Clinical Communication
• Clinical Skills and Practical Procedures
• Practicing in Egypt.
• Pathological Sciences: including histology, microbiology, virology, clinical biochemistry, etc.
• Professional Practice: including professionalism, personal development, ethics & law, etc.
• Social Determinants of Health: including psychological, social, cultural, and environmental factors impacting on health, health inequalities, health promotion, underserved groups, rural health, etc.
• Use of Evidence: accessing, critiquing, using and generating evidence for practice.
• Use of Medicines: pharmacology, therapeutics, prescribing, etc.

 The Foundation Year Program Guideline 

The Foundation Program is a structured, supervised workplace-based training program. It is designed to help foundation doctors to gain competence in essential clinical skills as well as other professional skills such as communication & teamwork. The program is typically made up of placements in a range of specialties over a period of two years. The placements provide a safe environment for the house officer (intern) to put what had been learned at medical school into practice, whilst giving you the additional skills, knowledge and experience needed to practice safely as a doctor.  

NGU interns will be trained in either the Cairo University or Ain Shams Hospitals with continuous supervision and facilitation by NGU faculty. 

Goals & Objectives 

The foundation program curriculum is based on educationally and clinically supervised, practice-based learning, underpinned at regular intervals by feedback, reflection on practice and assessment.  

Foundation doctors will be working to establish their professional identity in the workplace and learning to integrate and work effectively within multidisciplinary teams and the healthcare system as a whole. Also, to demonstrate that they are refining their skills and that they are able to take responsibility appropriately whilst recognizing and working within the limitations of their competence. They are expected to be responsible for their education and the development of their critical thinking and professional judgement.  

During the foundation program, they should reflect regularly on their performance and feedback that they have received. They should use this process to identify their strengths and to set targets for personal and professional development. By engaging in the educational and assessment processes, foundation doctors should fulfil their curricular requirements in preparation for entry into specialty or general practice training and will be able to demonstrate:  

• the ability to work adaptively in healthcare teams 
• the ability to manage patients with acute and chronic conditions 
• continuous improvement in their professional and clinical skills and reasoning
• increasing understanding of the healthcare environment 

At the end of each placement the clinical and educational supervisor will each provide a report to indicate whether the foundation doctor is making satisfactory progress The foundation doctors will always be encouraged to work with their supervisors to resolve any issues with their performance. 

By the end of the internship, the foundation doctor needs to be able to: 

1. Understand, apply, consolidate, and expand the knowledge and skills gained during the six years of medical curriculum. 
2. Be able to perform and document a patient evaluation by applying a targeted medical history with relevant physical examinations and to be able to reach to a meaningful differential diagnosis with the patient data gathered.
3. Be able to safely perform a set of basic medical procedures expected to be appropriate for the level of general physician. 
4. Be able to identify and screen the patients for common and non-critical diseases and to be able to provide primary care for such conditions.
5. Be able to identify and evaluate the patient requiring immediate medical attention, including emergency, critically ill and chronically deteriorating patients. 
6. Be able to perform basic emergency and life support procedures in case of need. 
7. Be able to demonstrate a professional and safe conduct during infection control, medical referrals, requesting expert opinion, clinical handovers, and adverse event reporting. 
8. Be able to have a clear and effective communication with patients, their family members, doctors, and other healthcare professionals. 
9. Be able to respect the roles and experience of co-workers and other healthcare professionals. 

10.Be able to work effectively as a member or leader of an inter-professional team and make appropriate referrals. 

               NGU students excel at maintaining a healthy balance between rigorous academics and varied extracurricular activities.  Likewise, NGU supports its students in this arduous but fruitful endeavor.  While these activities are numerous, highlighted below are only a few examples:

1. American Association for the Study of Liver Diseases- Egyptian Society for Liver Cancer Connect meeting2- Egyptian Ophthalmological Society
   NGU students attended the 2024 EOS conference, a comprehensive Ophthalmology conferences discussing numerous updates in this highly specialized branch of Medicine.3- Breast Cancer Awareness in Cooperation with Baheya Foundation4- Internal Medicine Scientific Club (IMSC)

Research Team:

Prof. Dr. Ahmed Ihab Abdelaziz, Director of HSRC and Research Group Leader.

Dr. Nada El-Ekiaby, Senior Scientist.

Dr. Injie Fawzy, Senior Scientist.

Dr. Shereen El Sobky, Postdoc.

Merna Hatem, Research Assistant.

Salma Fahim, Research Assistant.

Rowan Bahaa Eldin, Research Assistant.

Manon Ragheb, Research Assistant.

Amira Khaled, Research Assistant.

Miral Hamad, Senior Grants and Scientific Officer.

Research labs:
o Genomics and Proteomics Lab
o Cell Culture’s Lab
o Biosafety Lab
o Tissue Microarray Lab

Research areas:
o Cancer and Immunotherapy
o Molecular Cardiology
o Autoimmune Diseases
o Infectious Diseases

Awards:

• State Encouragement Award: Advanced Technological Medical Sciences by the Academy of Scientific Research and Technology (ASRT) awarded to Prof. Ahmed Ihab, Egypt 2015.
• Alexander Von Humboldt – Georg Forster Research Fellowship for experienced researchers – awarded to Prof. Ahmed Ihab, Germany 2017.
• Membership of the Egyptian reference Genome project awarded to Prof. Ahmed Ihab 2020.
• Membership of the WHO Panel of Experts who will inform the development of the WHO Collective Global Network for Rare Diseases (WHO CGN4RD) awarded to Prof. Ahmed Ihab 2021.
• Alexander Von Humboldt – Georg Forster Research Fellowship for postdoctoral researchers awarded to Dr. Nada El-Ekiaby, Germany 2019.

Application for ethics approval

SOM Code of ethics

SOM Publications (2016- June 2024)

• The use of urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin for diagnosis of hepato-renal syndrome in advanced cirrhotic patients. Abd Elaziz MA, Mustafa Gouda Elewa A, Zaki Mohamed Zaki Abdel Hamid D, Essam Soliman Ahmed Hassan N, Csongrádi É, Hamdy Hamouda Mohammed E, Abdel Gawad M. Ren Fail. 2024 Dec;46(1):2346284. Doi: 10.1080/0886022X.2024.2346284. PMID: 38757700

• Safety and efficacy of continuous intrathecal baclofen via cervical catheter tip: a retrospective case series. Mossner J, Abdelmageed S, Votoupal M, Misasi J, Saleh N, Dziugan K, Krater T, Raskin JS. Neurosurg Focus. 2024 Jun;56(6):E13.

Doi: 10.3171/2024.3.FOCUS2475. PMID: 38823059

• Melatonin counteracts polyethylene microplastics induced adreno-cortical damage in male albino rats. Farag AA, Bayoumi H, Radwaan SE, El Gazzar WB, Youssef HS, Nasr HE, Badr AM, Mansour HM, Elalfy A, Sayed AEH, Kharboush TG, Aboelkomsan EAF, Sliem RE, Ecotoxicol Environ Saf. 2024 May 27; 279:116499.

Doi: 10.1016/j.ecoenv.2024.116499. Online ahead of print. PMID: 38805828

• Exploring the risk of second primary malignancies in laryngeal cancer survivors: insights from the SEER database. Afify AY, Ashry MH. Eur Arch Otorhinolaryngol. 2024 May 22.

Doi: 10.1007/s00405-024-08731-9. Online ahead of print. PMID: 38775833

• A comparative study of different antiviral treatment protocols in HCV related cryoglobulinemic vasculitis. Allam WR, Hegazy MT, Hussein MA, Zoheir N, Quartuccio L, El-Khamisy SF, Ragab G. Sci Rep. 2024 May 23;14(1):11840. Doi: 10.1038/s41598-024-60490-z. PMID: 38782988

• Impact of HLA-B51 on Uveitis and Retinal Vasculitis: Data from the AIDA International Network Registries on Ocular Inflammatory Disorders. Sota J, Guerriero S, Lopalco G, Tufan A, Ragab G, AlMaglouth I, Govoni M, Sfikakis PP, Frassi M, Vitale A, Kardas RC, Triggianese P, Chimenti MS, Aboabat AA, Piga M, Monti S, Sebastiani GD, Yildirim D, Conforti A, Gentileschi S, Dammacco R, Hinojosa-Azaola A, Kawakami-Campos PA, Ruffilli F, Torres-Ruiz J, Thabet M, Atig A, Ruscitti P, Cataldi G, Viapiana O, Hatemi G, Karakoç A, Costi S, Iagnocco A, Crisafulli F, Fragoulis G, Del Giudice E, Hegazy MT, Paroli MP, Şahin A, Morrone M, Iannone F, Opris-Belinski D, Asfina KN, Barone P, Gaggiano C, Kucuk H, Gicchino MF, Carubbi F, Caggiano V, Laskari K, Tharwat S, Direskeneli H, Alibaz-Oner F, Sevik G, Maier A, Laymouna AH, Emmi G, Akkoç N, Tarsia M, Sbalchiero J, Conti G, Spinella R, La Torre F, Tombetti E, Amin RH, Mauro A, Karamanakos A, Carreño E, Fonollosa A, Cattalini M, Breda L, de-la-Torre A, Wiesik-Szewczyk E, Cifuentes-González C, Ozen S, Mazzei MA, Tosi GM, Frediani B, Balistreri A, Batu ED, Gupta V, Cantarini L, Fabiani C. Ocul Immunol Inflamm. 2024 May 17:1-8. doi: 10.1080/09273948.2024.2346815. Online ahead of print. PMID: 38759215

• Risk for cancer development in familial Mediterranean fever and associated predisposing factors: an ambidirectional cohort study from the international AIDA Network registries. Vitale A, Caggiano V, Tufan A, Ragab G, Batu ED, Portincasa P, Aragona E, Sota J, Conti G, De Paulis A, Rigante D, Olivieri AN, Şahin A, La Torre F, Lopalco G, Cattalini M, Maggio MC, Insalaco A, Sfikakis PP, Verrecchia E, Yildirim D, Kucuk H, Kardas RC, Laymouna AH, Ghanema M, Saad MA, Sener S, Ercan Emreol H, Ozen S, Jaber N, Khalil M, Di Ciaula A, Gaggiano C, Malizia G, Affronti A, Patroniti S, Romeo M, Sbalchiero J, Della Casa F, Mormile I, Silvaroli S, Gicchino MF, Çelik NÇ, Tarsia M, Karamanakos A, Hernández-Rodríguez J, Parronchi P, Opris-Belinski D, Barone P, Recke A, Costi S, Sfriso P, Giardini HAM, Gentileschi S, Wiesik-Szewczyk E, Vasi I, Loconte R, Jahnz-Różyk K, Martín-Nares E, Torres-Ruiz J, Cauli A, Conforti A, Emmi G, Li Gobbi F, Biasi GR, Terribili R, Ruscitti P, Del Giudice E, Tharwat S, Brucato AL, Ogunjimi B, Hinojosa-Azaola A, Balistreri A, Fabiani C, Frediani B, Cantarini L. Front Immunol. 2024 May 10; 15:1397890. Doi: 10.3389/fimmu.2024.1397890. eCollection 2024. PMID: 38799474

• Moving Together, Apart: Impacts of Travel Restrictions on a UK-Egypt Collaboration in Health Profession Education. Ragab L, Wassim M, Arfeen Z, Newman R, Rashid MA. J Med Educ Curric Dev. 2024 May 9; 11:23821205241253668. Doi: 10.1177/23821205241253668. eCollection 2024 Jan-Dec. PMID: 38736713 Free PMC article.

• Occipital nerve stimulation in pediatric patients with refractory occipital neuralgia. Mossner J, Saleh NB, Shahin MN, Rosenow JM, Raskin JS. Childs Nerv Syst. 2024 Apr 2.

Doi: 10.1007/s00381-024-06376-x. Online ahead of print. PMID: 38563970

• Optimized mucoadhesive niosomal carriers for intranasal delivery of carvedilol: A quality by design approach. Azrak ZAT, Taha MS, Jagal J, Elsherbeny A, Bayraktutan H, AbouGhaly MHH, Elshafeey AH, Greish K, Haider M. Int J Pharm. 2024 Apr 10;654:123935. Doi: 10.1016/j.ijpharm.2024.123935. Epub 2024 Feb 21. PMID: 38395319

• The association of FSCN1 (rs852479, rs1640233) and HOTAIR (rs920778) polymorphisms with the risk of breast cancer in Egyptian women. Galal ER, Abdelhakam DA, Ahmed LK, Elhusseny Y, Sayed SEP, Eltaweel NH. Mol Biol Rep. 2024 Apr 8;51(1):495. Doi: 10.1007/s11033-024-09459-9. PMID: 38587571

• Liver transplantation as an alternative for the treatment of intrahepatic cholangiocarcinoma: Past, present, and future directions. Kodali S, Connor AA, Thabet S, Brombosz EW, Ghobrial RM. Hepatobiliary Pancreat Dis Int. 2024 Apr;23(2):129-138.

Doi: 10.1016/j.hbpd.2023.07.007. Epub 2023 Jul 23. PMID: 37517983 Review.

• The Systemic Score May Identify Life-Threatening Evolution in Still Disease: Data from the GIRRCS AOSD-Study Group and the AIDA Network Still Disease Registry. Ruscitti P, Masedu F, Vitale A, Caggiano V, Di Cola I, Cipriani P, Valenti M, Mayrink Giardini HA, de Brito Antonelli IP, Dagostin MA, Lopalco G, Iannone F, Maria M, Almaghlouth IA, Asfina KN, Ali HH, Ciccia F, Iacono D, Pantano I, Mauro D, Sfikakis PP, Tektonidou M, Laskari K, Berardicurti O, Dagna L, Tomelleri A, Tufan A, Can Kardas R, Hinojosa-Azaola A, Martín-Nares E, Kawakami-Campos PA, Ragab G, Hegazy MT, Direskeneli H, Alibaz-Oner F, Fotis L, Sfriso P, Govoni M, La Torre F, Cristina Maggio M, Montecucco C, De Stefano L, Bugatti S, Rossi S, Makowska J, Del Giudice E, Emmi G, Bartoloni E, Hernández-Rodríguez J, Conti G, Nunzia Olivieri A, Gullo AL, Simonini G, Viapiana O, Wiesik-Szewczyk E, Erten S, Carubbi F, De Paulis A, Maier A, Tharwat S, Costi S, Iagnocco A, Sebastiani GD, Gidaro A, Brucato AL, Karamanakos A, Akkoç N, Caso F, Costa L, Prete M, Perosa F, Atzeni F, Guggino G, Fabiani C, Frediani B, Giacomelli R, Cantarini L. Arthritis Rheumatology. 2024 Mar 18. Doi: 10.1002/art.42845. Online ahead of print. PMID: 38499989

• Recurrent papulonodular herpes zoster, with syringitis, folliculitis, and vasculitis as clues to the diagnosis. Fawzy MM, El-Enany G, Abdelraouf SMA, Abdelkader HA. J Cutan Pathol. 2024 Mar;51(3):205-208.

Doi: 10.1111/cup.14566. Epub 2023 Dec 8. PMID: 38063075

• Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry. Tarsia M, Vitale A, Gaggiano C, Sota J, Maselli A, Bellantonio C, Guerriero S, Dammacco R, La Torre F, Ragab G, Hegazy MT, Fonollosa A, Paroli MP, Del Giudice E, Maggio MC, Cattalini M, Fotis L, Conti G, Mauro A, Civino A, Diomeda F, de-la-Torre A, Cifuentes-González C, Tharwat S, Hernández-Rodríguez J, Gómez-Caverzaschi V, Pelegrín L, Babu K, Gupta V, Minoia F, Ruscitti P, Costi S, Breda L, La Bella S, Conforti A, Mazzei MA, Carreño E, Amin RH, Grosso S, Frediani B, Tosi GM, Balistreri A, Cantarini L, Fabiani C. Ophthalmol Ther. 2024 Mar;13(3):761-774. doi: 10.1007/s40123-023-00863-1. Epub 2024 Jan 11. PMID: 38206518

• CCN3, POSTN, and PTHLH as potential key regulators of genomic integrity and cellular survival in iPSCs. Swaidan NT, Soliman NH, Aboughalia AT, Darwish T, Almeshal RO, Al-Khulaifi AA, Taha RZ, Alanany R, Hussein AY, Salloum-Asfar S, Abdulla SA, Abdallah AM, Emara MM. Front Mol Biosci. 2024 Feb 5; 11:1342011. Doi: 10.3389/fmolb.2024.1342011. eCollection 2024. PMID: 38375508

• Invited Response on: Effectiveness and Role of Using Hyaluronic Acid Injections for Gluteal Augmentation: A Comprehensive Systematic Review of Techniques and Outcomes. Mortada H, Alkadi D, Saqr H. Aesthetic Plast Surg. 2024 Jan 9. Doi: 10.1007/s00266-023-03806-0. Online ahead of print. PMID: 38195899

• Correction: Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry. Triggianese P, Vitale A, Lopalco G, Mayrink Giardini HA, Ciccia F, Al-Maghlouth I, Ruscitti P, Sfikakis PP, Iannone F, de Brito Antonelli IP, Patrone M, Asfina KN, Di Cola I, Laskari K, Gaggiano C, Tufan A, Sfriso P, Dagna L, Giacomelli R, Hinojosa-Azaola A, Ragab G, Fotis L, Direskeneli H, Spedicato V, Dagostin MA, Iacono D, Ali HH, Cipriani P, Sota J, Kardas RC, Bindoli S, Campochiaro C, Navarini L, Gentileschi S, Martín-Nares E, Torres-Ruiz J, Saad MA, Kourtesi K, Alibaz-Oner F, Sevik G, Iagnocco A, Makowska J, Govoni M, Monti S, Maggio MC, La Torre F, Del Giudice E, Hernández-Rodríguez J, Bartoloni E, Emmi G, Chimenti MS, Maier A, Simonini G, Conti G, Olivieri AN, Tarsia M, De Paulis A, Lo Gullo A, Więsik-Szewczyk E, Viapiana O, Ogunjimi B, Tharwat S, Erten S, Nuzzolese R, Karamanakos A, Frassi M, Conforti A, Caggiano V, Marino A, Sebastiani GD, Gidaro A, Tombetti E, Carubbi F, Rubegni G, Cartocci A, Balistreri A, Fabiani C, Frediani B, Cantarini L. Intern Emerg Med. 2024 Jan;19(1):255-257. Doi: 10.1007/s11739-023-03511-5. PMID: 38151591

• Epigenetic alterations of miR-155 and global DNA methylation as potential mediators of ochratoxin A cytotoxicity and carcinogenicity in human lung fibroblasts. Kharboush TG, Ahmed IA, Farag AA, Kharboush T, Sayed AEH, Abdel-Kareim AM, Al Mohaini M, Attia H, Eid RA, Zaki MSA, Al-Tabbakh AM. Environ Sci Pollut Res Int. 2024 Jan;31(4):5473-5483. Doi: 10.1007/s11356-023-31283-0. Epub 2023 Dec 20. PMID: 38114706

• Integrating AI and ML in Myelodysplastic Syndrome Diagnosis: State-of-the-Art and Future Prospects. Elshoeibi AM, Badr A, Elsayed B, Metwally O, Elshoeibi R, Elhadary MR, Elshoeibi A, Attya MA, Khadadah F, Alshurafa A, Alhuraiji A, Yassin M. Cancers (Basel). 2023 Dec 22;16(1):65. Doi: 10.3390/cancers16010065. PMID: 38201493 Free PMC article. Review.

• Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease. Vitale A, Caggiano V, Sfikakis PP, Dagna L, Lopalco G, Ragab G, La Torre F, Almaghlouth IA, Maggio MC, Sota J, Tufan A, Hinojosa-Azaola A, Iannone F, Loconte R, Laskari K, Direskeneli H, Ruscitti P, Morrone M, Mayrink Giardini HA, Panagiotopoulos A, Di Cola I, Martín-Nares E, Monti S, De Stefano L, Kardas RC, Duran R, Campochiaro C, Tomelleri A, Alabdulkareem AM, Gaggiano C, Tarsia M, Bartoloni E, Romeo M, Hussein MA, Laymouna AH, Parente de Brito Antonelli I, Dagostin MA, Fotis L, Bindoli S, Navarini L, Alibaz-Oner F, Sevik G, Frassi M, Ciccia F, Iacono D, Crisafulli F, Portincasa P, Jaber N, Kawakami-Campos PA, Wiesik-Szewczyk E, Iagnocco A, Simonini G, Sfriso P, Balistreri A, Giacomelli R, Conti G, Frediani B, Fabiani C, Cantarini L. Front Med (Lausanne). 2023 Dec 12; 10:1256243. Doi: 10.3389/fmed.2023.1256243. eCollection 2023. PMID: 38148914

• Still’s disease continuum from childhood to elderly: data from the international AIDA Network Still’s disease registry. Vitale A, Caggiano V, Lopalco G, Mayrink Giardini HA, Ciccia F, Almaghlouth IA, Ruscitti P, Sfikakis PP, Tufan A, Dagna L, Giacomelli R, Hinojosa-Azaola A, Ragab G, Direskeneli H, Fotis L, Sota J, Iannone F, Morrone M, de Brito Antonelli IP, Dagostin MA, Iacono D, Patrone M, Asfina K, Alanazi F, Di Cola I, Gaggiano C, Tektonidou MG, Kardas RC, Kucuk H, Campochiaro C, Tomelleri A, Navarini L, Berardicurti O, Martín-Nares E, Torres-Ruiz J, Mahmoud AAA, Alibaz-Oner F, Kourtesi K, Tarsia M, Sfriso P, Makowska J, Govoni M, La Torre F, Maggio MC, Monti S, Del Giudice E, Emmi G, Bartoloni E, Hernández-Rodríguez J, Gómez-Caverzaschi V, Maier A, Simonini G, Iagnocco A, Conti G, Olivieri AN, De Paulis A, Lo Gullo A, Viapiana O, Wiesik-Szewczyk E, Erten S, Ogunjimi B, Carubbi F, Tharwat S, Laskari K, Costi S, Triggianese P, Karamanakos A, Conforti A, Frassi M, Sebastiani GD, Gidaro A, Mauro A, Balistreri A, Fabiani C, Frediani B, Cantarini L. RMD Open. 2023 Dec 1;9(4): e003578. doi: 10.1136/rmdopen-2023-003578. PMID: 38053457

• Effectiveness and Role of Using Hyaluronic Acid Injections for Gluteal Augmentation: A Comprehensive Systematic Review of Techniques and Outcomes. Mortada H, Alkadi D, Saqr H, Sultan F, Alturaiki B, Alrobaiea S, Aljaaly HA, Arab K, Arkoubi AY. Aesthetic Plast Surg. 2023 Dec;47(6):2719-2733. doi: 10.1007/s00266-023-03458-0. Epub 2023 Jul 5. PMID: 37407710 Review.

• Detection of AZFc gene deletion in a cohort of Egyptian patients with idiopathic male infertility. Eid MM, Eid OM, Abdelrahman AH, Abdelrahman IFS, Aboelkomsan EAF, AbdelKader RMA, Hassan M, Farid M, Ibrahim AA, Abd El-Fattah SN, Mahrous R. J Genet Eng Biotechnol. 2023 Nov 10;21(1):111. Doi: 10.1186/s43141-023-00584-9. PMID: 37947911

• SGLT-2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model. Mahmoud MM, Rashed LA, Soliman SA, Sayed SM, Kamel O, Kamar SS, Hussien RES. Physiol Rep. 2023 Nov;11(22): e15858. Doi: 10.14814/phy2.15858. PMID: 37985173 Free PMC article.

• Early Cost-Utility Analysis of Ataluren and Eteplirsen in the Treatment of Duchenne Muscular Dystrophy in Egypt. Shehata Z, Metry A, Rabea H, El Sherif R, Abdelrahim M, Dawoud D. Value Health Reg Issues. 2023 Nov; 38:109-117. Doi: 10.1016/j.vhri.2023.08.004. Epub 2023 Oct 18. PMID: 37862859

• Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry. Ruscitti P, Masedu F, Vitale A, Di Cola I, Caggiano V, Di Muzio C, Cipriani P, Valenti M, Berardicurti O, Navarini L, Iacono D, Pantano I, Mauro D, Ciccia F, Rossi S, De Stefano L, Monti S, Bugatti S, Montecucco C, Caso F, Costa L, Prete M, Perosa F, Iagnocco A, Atzeni F, Guggino G, Giardini H, Antonelli IPB, Almaghlouth IA, Asfina K, Direskeneli H, Alibaz-Oner F, Sevik G, Tufan A, Sfikakis PP, La Torre F, Hinojosa-Azaola A, Martín-Nares E, Torres-Ruiz J, Ragab G, Maggio MC, Makowska J, Del Giudice E, Bartoloni E, Emmi G, Govoni M, Lo Gullo A, Lopalco G, Simonini G, Fotis L, Ogunjimi B, Tharwat S, Frediani B, Maier A, Carubbi F, Dagna L, Erten S, Gidaro A, Hernández-Rodríguez J, Sfriso P, Fabiani C, Giacomelli R, Cantarini L. RMD Open. 2023 Nov;9(4): e003419. doi: 10.1136/rmdopen-2023-003419. PMID: 37989322

• Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry. Triggianese P, Vitale A, Lopalco G, Mayrink Giardini HA, Ciccia F, Al-Maghlouth I, Ruscitti P, Sfikakis PP, Iannone F, de Brito Antonelli IP, Patrone M, Asfina KN, Di Cola I, Laskari K, Gaggiano C, Tufan A, Sfriso P, Dagna L, Giacomelli R, Hinojosa-Azaola A, Ragab G, Fotis L, Direskeneli H, Spedicato V, Dagostin MA, Iacono D, Ali HH, Cipriani P, Sota J, Kardas RC, Bindoli S, Campochiaro C, Navarini L, Gentileschi S, Martín-Nares E, Torres-Ruiz J, Saad MA, Kourtesi K, Alibaz-Oner F, Sevik G, Iagnocco A, Makowska J, Govoni M, Monti S, Maggio MC, La Torre F, Del Giudice E, Hernández-Rodríguez J, Bartoloni E, Emmi G, Chimenti MS, Maier A, Simonini G, Conti G, Olivieri AN, Tarsia M, De Paulis A, Lo Gullo A, Więsik-Szewczyk E, Viapiana O, Ogunjimi B, Tharwat S, Erten S, Nuzzolese R, Karamanakos A, Frassi M, Conforti A, Caggiano V, Marino A, Sebastiani GD, Gidaro A, Tombetti E, Carubbi F, Rubegni G, Cartocci A, Balistreri A, Fabiani C, Frediani B, Cantarini L. Intern Emerg Med. 2023 Nov;18(8):2231-2243. doi: 10.1007/s11739-023-03408-3. Epub 2023 Oct 12. PMID: 37828268 Free PMC article.

• Revolutionizing chronic lymphocytic leukemia diagnosis: A deep dive into the diverse applications of machine learning. Elhadary M, Elshoeibi AM, Badr A, Elsayed B, Metwally O, Elshoeibi AM, Mattar M, Alfarsi K, AlShammari S, Alshurafa A, Yassin M. Blood Rev. 2023 Nov;62:101134. doi: 10.1016/j.blre.2023.101134. Epub 2023 Sep 22. PMID: 37758527 Review.

• The administration of methotrexate in patients with Still’s disease, “real-life” findings from AIDA Network Still Disease Registry. Ruscitti P, Sota J, Vitale A, Lopalco G, Iannone F, Morrone M, Giardini HAM, D’Agostin MA, Antonelli IPB, Almaghlouth I, Asfina KN, Khalil N, Sfikakis PP, Laskari K, Tektonidou M, Ciccia F, Iacono D, Riccio F, Ragab G, Hussein MA, Govoni M, Ruffilli F, Direskeneli H, Alibaz-Oner F, Giacomelli R, Navarini L, Bartoloni E, Riccucci I, Martín-Nares E, Torres-Ruiz J, Cipriani P, Di Cola I, Hernández-Rodríguez J, Gómez-Caverzaschi V, Dagna L, Tomelleri A, Makowska J, Brzezinska O, Iagnocco A, Bellis E, Caggiano V, Gaggiano C, Tarsia M, Mormile I, Emmi G, Sfriso P, Monti S, Erten Ş, Del Giudice E, Lubrano R, Conti G, Olivieri AN, Lo Gullo A, Tharwat S, Karamanakos A, Gidaro A, Maggio MC, La Torre F, Cardinale F, Ogunjimi B, Maier A, Sebastiani GD, Opris-Belinski D, Frassi M, Viapiana O, Bizzi E, Carubbi F, Fotis L, Tufan A, Kardas RC, Więsik-Szewczyk E, Jahnz-Różyk K, Fabiani C, Frediani B, Balistreri A, Rigante D, Cantarini L. Semin Arthritis Rheum. 2023 Oct; 62:152244. Doi: 10.1016/j.semarthrit.2023.152244. Epub 2023 Jul 21. PMID: 37517110

• Preliminary Study of sCD14 and sCD163 as Predictors of Disease Severity and ICU Admission in COVID-19: Relation to Hematological Parameters, Blood Morphological Changes, and Inflammatory Biomarkers. Attia H, El Nagdy M, Abdel Halim RM. Mediterr J Hematol Infect Dis. 2023 Sep 1;15(1): e2023046. Doi: 10.4084/MJHID.2023.046. eCollection 2023. PMID: 37705527

• Melatonin Alleviates Intestinal Barrier Damaging Effects Induced by Polyethylene Microplastics in Albino Rats. El Gazzar WB, Sliem RE, Bayoumi H, Nasr HE, Shabanah M, Elalfy A, Radwaan SE, Gebba MA, Mansour HM, Badr AM, Amer MF, Ashour SS, Morsi H, Aboelkomsan ESAF, Baioumy B, Sayed AEH, Farag AA. Int J Mol Sci. 2023 Sep 3;24(17):13619. Doi: 10.3390/ijms241713619. PMID: 37686424

• Letter to the Editor Regarding “Outcomes of Intramuscular Gluteal Augmentation with Implants Using Tumescent Local Anesthesia“. Saqr H, El Fahar MH. Aesthetic Plast Surg. 2023 Aug 28. doi: 10.1007/s00266-023-03585-8. Online ahead of print. PMID: 37639025

• Using the Health Belief Model to assess COVID-19 perceptions and behaviours among a group of Egyptian adults: a cross-sectional study. Boulos DNK, Hassan AM. BMC Public Health. 2023 Aug 25;23(1):1624. doi: 10.1186/s12889-023-16513-x. PMID: 37626356 Free PMC article.

• Autoinflammatory diseases and the kidney. Hegazy MT, Fayed A, Nuzzolese R, Sota J, Ragab G. Immunol Res. 2023 Aug;71(4):578-587. Doi: 10.1007/s12026-023-09375-3. Epub 2023 Mar 29. PMID: 36991303. Review.

• Twitter as Educational Tool: A Global Web-Based Cross-Sectional Study on Social Media Behavior of Nephrologists. Sharma S, Tannor EK, Duarsa R, Kar S, Gawad MA, Agrawal KK, Nlandu YM, Orantes-Navarro CM, Sharma N, Anandh U. Kidney Int Rep. 2023 Aug 19;8(11):2469-2473. Doi: 10.1016/j.ekir.2023.08.009. eCollection 2023 Nov. PMID: 38025224

• Evolution of Superficial Muscular Aponeurotic System Facelift Techniques: A Comprehensive Systematic Review of Complications and Outcomes. Mortada H, Alkilani N, Halawani IR, Zaid WA, Alkahtani RS, Saqr H, Neel OF. JPRAS Open. 2023 Jun 8; 39:166-180. Doi: 10.1016/j.jpra.2023.06.003. eCollection 2024 Mar. PMID: 38283861 Review.

• Causes of death among patients with cutaneous melanoma: a US population-based study. Sadeq MA, Ashry MH, Ghorab RMF, Afify AY. Sci Rep. 2023 Jun 24;13(1):10257. doi: 10.1038/s41598-023-37333-4. PMID: 37355743

• A patient-driven registry on Behçet’s disease: the AIDA for patients pilot project. Gaggiano C, Del Bianco A, Sota J, Gentileschi S, Ruscitti P, Giacomelli R, Piga M, Crisafulli F, Monti S, Emmi G, De Paulis A, Vitale A, Tarsia M, Caggiano V, Nuzzolese R, Parretti V, Fabiani C, Lopalco G, Maier A, Cattalini M, Rigante D, Govoni M, Li Gobbi F, Guiducci S, Parronchi P, Marino A, Ciccia F, Maggio MC, Aragona E, Bartoloni E, Iagnocco A, Viapiana O, Sebastiani GD, Guerriero S, Insalaco A, Del Giudice E, Conti G, Barone P, Olivieri AN, Brucato A, Carubbi F, Triggianese P, Mauro A, Tosi GM, Fonollosa A, Giardini HAM, Ragab G, Tharwat S, Hernández-Rodríguez J, Sfikakis PP, Laskari K, Karamanakos A, Espinosa G, Shahram F, Direskeneli H, Hinojosa-Azaola A, Opris-Belinski D, AlMaghlouth IA, Hatemi G, Eksin MA, Önen F, Więsik-Szewczyk E, Akkoç N, Tufan A, Şahin A, Erten Ş, Ozen S, Batu ED, Frediani B, Balistreri A, Cantarini L. Front Med (Lausanne). 2023 Jun 16; 10:1188021. doi: 10.3389/fmed.2023.1188021. eCollection 2023. PMID: 37396916

• Axial spondyloarthritis in patients with recurrent fever attacks: data from the AIDA network registry for undifferentiated autoInflammatory diseases (USAIDs). Vitale A, Caggiano V, Silva I, Oliveira DG, Ruscitti P, Ciccia F, Vasi I, Tufan A, Lopalco G, AlMaghlouth IA, Sota J, Wiesik-Szewczyk E, Gaggiano C, Giardini HAM, Spedicato V, Ragab G, Iannone F, Balistreri A, Frassi M, Hernández-Rodríguez J, Fabiani C, Falsetti P, Di Meglio N, Frediani B, Mazzei MA, Rigante D, Faria R, Cantarini L. Front Med (Lausanne). 2023 May 30; 10:1195995. doi: 10.3389/fmed.2023.1195995. eCollection 2023. PMID: 37324154.

• Kasr Alainy simplified uterine preserving surgery for conservative management of placenta accreta spectrum (PAS): A modified surgical approach. Mousa A, Elkhateb IT, Gaafar HM, Elsherbini MM, Mousa H, Abdalla M, Abdelbar A, Rida D, Majd HS, Collins SL. Eur J Obstet Gynecol Reprod Biol. 2023 May;284:150-161. Doi: 10.1016/j.ejogrb.2023.03.026. Epub 2023 Mar 24. PMID: 37001252

• Causes of death after laryngeal cancer diagnosis: A US population-based study. Afify AY, Ashry MH, Sadeq MA, Elsaid M. Eur Arch Otorhinolaryngol. 2023 Apr;280(4):1855-1864. doi: 10.1007/s00405-022-07730-y. Epub 2022 Nov 10. PMID: 36357608

• The precision of two alternative indirect workflows for digital model production: an illusion or a possibility? Elkersh NM, Fahmy RA, Zayet MK, Gaweesh YS, Hassan MG. Clin Oral Investig. 2023 Jul;27(7):3787-3797. Doi: 10.1007/s00784-023-04996-2. Epub 2023 Apr 13 PMID: 37046002

• Causes of death after laryngeal cancer diagnosis: A US population-based study. Afify AY, Ashry MH, Sadeq MA, Elsaid M. Eur Arch Otorhinolaryngol. 2023 Apr;280(4):1855-1864. doi: 10.1007/s00405-022-07730-y. Epub 2022 Nov 10. PMID: 36357608

• Musculoskeletal manifestations in children with Behçet’s syndrome: data from the AIDA Network Behçet’s Syndrome Registry. Gaggiano C, Maselli A, Sfikakis PP, Laskari K, Ragab G, Hegazy MT, Laymouna AH, Lopalco G, Almaghlouth IA, Asfina KN, Alahmed O, Giardini Mayrink HA, Parente de Brito Antonelli I, Cattalini M, Piga M, Sota J, Gentileschi S, Maggio MC, Opris-Belinski D, Hatemi G, Insalaco A, Olivieri AN, Tufan A, Karadeniz H, Kardaş RC, La Torre F, Cardinale F, Marino A, Guerriero S, Ruscitti P, Tarsia M, Vitale A, Caggiano V, Telesca S, Iannone F, Parretti V, Frassi M, Aragona E, Ciccia F, Wiesik-Szewczyk E, Ionescu R, Şahin A, Akkoç N, Hinojosa-Azaola A, Tharwat S, Hernández-Rodríguez J, Espinosa G, Conti G, Del Giudice E, Govoni M, Emmi G, Fabiani C, Balistreri A, Frediani B, Rigante D, Cantarini L; AIDA Network. Intern Emerg Med. 2023 Apr;18(3):743-754. doi: 10.1007/s11739-023-03215-w. Epub 2023 Mar 7. PMID: 36881285. Clinical Trial.

• MicroRNA-122 mimic/microRNA-221 inhibitor combination as a novel therapeutic tool against hepatocellular carcinoma. Hassan M, Elzallat M, Aboushousha T, Elhusseny Y, El-Ahwany E. Noncoding RNA Res. 2022 Nov 23;8(1):126-134. doi: 10.1016/j.ncrna.2022.11.005. eCollection 2023 PMID: 36474748 Free PMC article.

• Incidence trends of gastric cancer among adolescents and young adults. Afify AY. J Gastroenterol Hepatol. 2023 Feb;38(2):337. Doi: 10.1111/jgh.16095. Epub 2023 Jan 4. PMID: 36575947

• Combination of acitretin and narrowband UV-B for the treatment of vitiligo: A new treatment modality with an impact on tissue E-cadherin expression. Ramadan S, Zeid OA, Esmat S, Saleh NA, Assaf M, Hilal RF. J Am Acad Dermatol. 2023 Jan;88(1):241-243. doi: 10.1016/j.jaad.2022.05.012. Epub 2022 May 13. PMID: 35569592

• Estimating Societal Cost of Illness and Patients’ Quality of Life of Duchenne Muscular Dystrophy in Egypt. Shehata ZH, Rabea H, El Sherif R, Abdelrahim ME, Dawoud DM. Value Health Reg Issues. 2023 Jan; 33:10-16. doi: 10.1016/j.vhri.2022.08.006. Epub 2022 Sep 23. PMID: 36162195

• Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry. Vitale A, Caggiano V, Maggio MC, Lopalco G, Emmi G, Sota J, La Torre F, Ruscitti P, Bartoloni E, Conti G, Fabiani C, Mattioli I, Gaggiano C, Cardinale F, Dagna L, Campochiaro C, Giacomelli R, Balistreri A, Laskari K, Tufan A, Ragab G, Almaghlouth IA, Więsik-Szewczyk E, Pereira RM, Frediani B, Iannone F, Sfikakis PP, Cantarini L. Front Med (Lausanne). 2022 Dec 22; 9:1071732. doi: 10.3389/fmed.2022.1071732. eCollection 2022. PMID: 36619631.

• Blood transfusion in autoimmune rheumatic diseases. Goubran H, Ragab G, Seghatchian J, Burnouf T. Transfus Apher Sci. 2022 Dec;61(6):103596. doi: 10.1016/j.transci.2022.103596. Epub 2022 Oct 28. PMID: 36371394

• Regulation of IGF2BP1 by miR-186 and its impact on downstream lncRNAs H19, FOXD2-AS1, and SNHG3 in HCC. Habashy DA, Hamad MHM, Ragheb M, Khalil ZA, El Sobky SA, Hosny KA, Esmat G, El-Ekiaby N, Fawzy IO, Abdelaziz AI. Life Sci. 2022 Dec 1; 310:121075. Doi: 10.1016/j.lfs.2022.121075. Epub 2022 Oct 13. PMID: 36243115

• Regulation of lipid droplet (LD) formation in hepatocytes via regulation of SREBP1c by non-coding RNAs. El Sobky SA, Aboud NK, El Assaly NM, Fawzy IO, El-Ekiaby N, Abdelaziz AI. Front Med (Lausanne). 2022 Sep 20; 9:903856. Doi: 10.3389/fmed.2022.903856. eCollection 2022. PMID: 36203751 Free PMC article.

• Efficacy and safety of tocilizumab in adult-onset Still’s disease: Real-life experience from the international AIDA registry. Sota J, Vitale A, Lopalco G, Pereira RMR, Giordano HF, Antonelli IPB, Makowska J, Brzezińska O, Lewandowska-Polak A, Ruscitti P, Cipriani P, Cola ID, Govoni M, Ruffili F, Sfikakis PP, Laskari K, Ragab G, Hussein MA, Gentileschi S, Gaggiano C, La Torre F, Maier A, Emmi G, Marino A, Ciccia F, Sfriso P, Maggio MC, Bartoloni E, Lomater C, Hegazy MT, Tektonidou M, Dagostin MA, Opinc A, Sebastiani GD, Giacomelli R, Giudice ED, Olivieri AN, Tufan A, Kardas RK, Nuzzolese R, Cardinale F, Więsik-Szewczyk E, Veronica P, Tarsia M, Iannone F, Della Casa F, Fabiani C, Frediani B, Balistreri A, Rigante D, Cantarini L. Semin Arthritis Rheum. 2022 Dec; 57:152089. Doi: 10.1016/j.semarthrit.2022.152089. Epub 2022 Aug 30. PMID: 36063578

• SARS-CoV-2 and cancer: the intriguing and informative cross-talk. Goubran H, Stakiw J, Seghatchian J, Ragab G, Burnouf T. Transfus Apher Sci. 2022 Aug;61(4):103488. Doi: 10.1016/j.transci.2022.103488. Epub 2022 Jun 14. PMID: 35753906 Free PMC article.

• Evaluation of needling/microneedling as an adjunct to phototherapy in the treatment of stable acral vitiligo: a comparative clinical and immunohistochemical study. Esmat S, Assaf MI, Mohye Eldeen R, Gawdat HI, Saadi DG. J Dermatolog Treat. 2022 Aug;33(5):2621-2628. Doi: 10.1080/09546634.2022.2062279. Epub 2022 Apr 8. PMID: 35373693 Clinical Trial.

• Development and implementation of the AIDA International Registry for patients with Behçet’s disease. Vitale A, Della Casa F, Ragab G, Almaghlouth IA, Lopalco G, Pereira RM, Guerriero S, Govoni M, Sfikakis PP, Giacomelli R, Ciccia F, Monti S, Ruscitti P, Piga M, Lomater C, Tufan A, Opris-Belinski D, Emmi G, Hernández-Rodríguez J, Şahin A, Sebastiani GD, Bartoloni E, Akkoç N, Gündüz ÖS, Cattalini M, Conti G, Hatemi G, Maier A, Parronchi P, Del Giudice E, Erten S, Insalaco A, Li Gobbi F, Maggio MC, Shahram F, Caggiano V, Hegazy MT, Asfina KN, Morrone M, Prado LL, Dammacco R, Ruffilli F, Arida A, Navarini L, Pantano I, Cavagna L, Conforti A, Cauli A, Marucco EM, Kucuk H, Ionescu R, Mattioli I, Espinosa G, Araújo O, Karkaş B, Canofari C, Sota J, Laymouna AH, Bedaiwi AA, Colella S, Giardini HAM, Albano V, Lo Monaco A, Fragoulis GE, Kardas RC, Berlengiero V, Hussein MA, Ricci F, La Torre F, Rigante D, Więsik-Szewczyk E, Frassi M, Gentileschi S, Tosi GM, Dagostin MA, Mahmoud AAA, Tarsia M, Alessio G, Cimaz R, Giani T, Gaggiano C, Iannone F, Cipriani P, Mourabi M, Spedicato V, Barneschi S, Aragona E, Balistreri A, Frediani B, Fabiani C, Cantarini L; Autoinflammatory Diseases Alliance (AIDA) Network. Intern Emerg Med. 2022 Oct;17(7):1977-1986. Doi: 10.1007/s11739-022-03038-1. Epub 2022 Jul 14. PMID: 35831701

• Development and Implementation of the AIDA International Registry for Patients with VEXAS Syndrome. Vitale A, Caggiano V, Della Casa F, Hernández-Rodríguez J, Frassi M, Monti S, Tufan A, Telesca S, Conticini E, Ragab G, Lopalco G, Almaghlouth I, Pereira RMR, Yildirim D, Cattalini M, Marino A, Giani T, La Torre F, Ruscitti P, Aragona E, Wiesik-Szewczyk E, Del Giudice E, Sfikakis PP, Govoni M, Emmi G, Maggio MC, Giacomelli R, Ciccia F, Conti G, Ait-Idir D, Lomater C, Sabato V, Piga M, Sahin A, Opris-Belinski D, Ionescu R, Bartoloni E, Franceschini F, Parronchi P, de Paulis A, Espinosa G, Maier A, Sebastiani GD, Insalaco A, Shahram F, Sfriso P, Minoia F, Alessio M, Makowska J, Hatemi G, Akkoç N, Li Gobbi F, Gidaro A, Olivieri AN, Al-Mayouf SM, Erten S, Gentileschi S, Vasi I, Tarsia M, Mahmoud AAA, Frediani B, Fares Alzahrani M, Laymouna AH, Ricci F, Cardinale F, Jahnz-Rózyk K, Tosi GM, Crisafulli F, Balistreri A, Dagostin MA, Ghanema M, Gaggiano C, Sota J, Di Cola I, Fabiani C, Giardini HAM, Renieri A, Fabbiani A, Carrer A, Bocchia M, Caroni F, Rigante D, Cantarini L. Front Med (Lausanne). 2022 Jul 11; 9:926500. Doi: 10.3389/fmed.2022.926500. eCollection 2022. PMID: 35899212.

• Platelet and extracellular vesicles in COVID-19 infection and its vaccines. Goubran H, Seghatchian J, Sabry W, Ragab G, Burnouf T. Transfus Apher Sci. 2022 Jun;61(3):103459. Doi: 10.1016/j.transci.2022.103459. Epub 2022 May 21. PMID: 35654711 Free PMC article. Review.

• Evaluation of the ex-vivo porcine simulator on EUS-guided cystogastrostomy using lumen-apposing metal stent training. Ibrahim M, Roshdy N, Taleb A, Alfadda A, Al-Lehibi A, Altonbary A, Galal A, El-Fouly A, Kozlowska A, Khor C, Isayama H, Okasha H, Barthet M, Giovannini M, Pausawasdi N, Eisendrath P, Kongkam P, Ratanachu-Ek T, Nakai Y. Endosc Ultrasound. 2022 May-Jun;11(3):201-207. doi: 10.4103/EUS-D-21-00109. PMID: 35708369

• Development and Implementation of the AIDA International Registry for Patients With Still’s Disease. Vitale A, Della Casa F, Lopalco G, Pereira RM, Ruscitti P, Giacomelli R, Ragab G, La Torre F, Bartoloni E, Del Giudice E, Lomater C, Emmi G, Govoni M, Maggio MC, Maier A, Makowska J, Ogunjimi B, Sfikakis PP, Sfriso P, Gaggiano C, Iannone F, Dagostin MA, Di Cola I, Navarini L, Ahmed Mahmoud AA, Cardinale F, Riccucci I, Paroli MP, Marucco EM, Mattioli I, Sota J, Abbruzzese A, Antonelli IPB, Cipriani P, Tufan A, Fabiani C, Ramadan MM, Cattalini M, Kardas RC, Sebastiani GD, Giardini HAM, Hernández-Rodríguez J, Mastrorilli V, Więsik-Szewczyk E, Frassi M, Caggiano V, Telesca S, Giordano HF, Guadalupi E, Giani T, Renieri A, Colella S, Cataldi G, Gentile M, Fabbiani A, Al-Maghlouth IA, Frediani B, Balistreri A, Rigante D, Cantarini L. Front Med (Lausanne). 2022 Apr 7; 9:878797. Doi: 10.3389/fmed.2022.878797. eCollection 2022. PMID: 35463015 Free PMC article.

• Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis. Casa FD, Vitale A, Guerriero S, Sota J, Cimaz R, Ragab G, Ruscitti P, Pereira RMR, Minoia F, Del Giudice E, Emmi G, Lomater C, Monti S, Canofari C, Gaggiano C, Alessio G, Miserocchi E, Conforti A, Dagostin MA, Mapelli C, Paroli MP, Parretti V, Albano V, Favale R, Marelli L, Hegazy MT, Cipriani P, Antonelli IPB, Caggiano V, Aragona E, Laymouna AH, Tosi GM, Tarsia M, Cattalini M, La Torre F, Lopalco G, Więsik-Szewczyk E, Frassi M, Gentileschi S, Giordano HF, Frediani B, Shinjo SK, Rigante D, Sfikakis PP, Balistreri A, Hussein MA, Amin RH, Cantarini L, Fabiani C; Autoinflammatory Diseases Alliance (AIDA) Network. Ophthalmol Ther. 2022 Apr;11(2):899-911. Doi: 10.1007/s40123-022-00459-1. Epub 2022 Jan 31. PMID: 35099782

• Frailty and Suicidality in Older Adults: A Mini-Review and Synthesis.

Shah J, Kandil OA, Mortagy M, Abdelhameed A, Shah A, Kuron M, Abdellatif YO. Gerontology. 2022;68(5):571-577. doi: 10.1159/000523789. Epub 2022 Apr 13. PMID: 35417914

• Online medical education in Egypt during the COVID-19 pandemic: a nationwide assessment of medical students’ usage and perceptions. Mortagy M, Abdelhameed A, Sexton P, Olken M, Hegazy MT, Gawad MA, Senna F, Mahmoud IA, Shah J; Egyptian Medical Education Collaborative Group (EGY MedEd); Aiash H. BMC Med Educ. 2022 Mar 30;22(1):218. doi: 10.1186/s12909-022-03249-2. PMID: 35354406 Free PMC article. Review.

• Challenges and Opportunities of a Virtual Nephrology Meeting: The ISN World Congress of Nephrology 2021. Claure-Del Granado R, Anandh U, Lerma E, Conjeevaram A, Arce-Amaré F, Dos Santos ACS Jr, Basu G, Bek S, Dhakal AK, Gawad MA, AkL A, Turgut D, Karam S, Bajpai D, Pecoits-Filho R, Parikh N. Kidney Int Rep. 2022 Feb;7(2):133-137. Doi: 10.1016/j.ekir.2021.11.039. Epub 2021 Dec 8. PMID: 35036661

• Hepatocellular carcinoma cell line-microenvironment induced cancer-associated phenotype, genotype, and functionality in mesenchymal stem cells. Salah RA, Nasr MA, El-Derby AM, Abd Elkodous M, Mohamed RH, El-Ekiaby N, Osama A, Elshenawy SE, Hamad MHM, Magdeldin S, Gabr MM, Abdelaziz AI, El-Badri NS. Life Sci. 2022 Jan 1; 288:120168. Doi: 10.1016/j.lfs.2021.120168. Epub 2021 Nov 23. PMID: 34826437

• Breaking Borders: How Barriers to Global Mobility Hinder International Partnerships in Academic Medicine. Wondimagegn D, Ragab L, Yifter H, Wassim M, Rashid MA, Whitehead CR, Gill D, Soklaridis S. Acad Med. 2022 Jan 1;97(1):37-40. Doi: 10.1097/ACM.0000000000004257. PMID: 34323859 Free PMC article.

• The curious case of miR-155 in SLE. Ibrahim SA, Afify AY, Fawzy IO, El-Ekiaby N, Abdelaziz AI. Expert Rev Mol Med. 2021 Sep 1;23: e11. Doi: 10.1017/erm.2021.11. PMID: 34470679 Review.

• PPAR agonists as effective adjuvants for COVID-19 vaccines, by modifying immunogenetics: a review of literature. AbdelMassih AF, Menshawey R, Ismail JH, Husseiny RJ, Husseiny YM, Yacoub S, Kamel A, Hozaien R, Yacoub E, Menshawey E, Abdelmalek A, Abouelazaem A, Elhatw A, Aboelmaaty A, Shahib A, Mansour A, Kamal A, Mohamed B, Atif B, Ghabreal B, Abdelmalak C, Ibrahim D, Elsaify E, Magdy F, Hanna FG, Hafez H, Dahir H, Merhom K, Ahmed M, Bishara M, Tawfik M, Youssef M, El Sharnouby M, Hamouda M, Ammar M, Ali N, Daniel N, El-Husseiny N, Abdelraouf N, Abdelhameed NK, Ahmed R, Othman R, Mohamadein R, Allam R, Elgendy R, Shebl R, Elsherbiney S, Fouad S, Emel S, Owais S, Hetta S, El-Saman S, Abdelalim S, Galal S, Asar Y, Osman Y, Khalaf Y, Aziz Y, Khafagy Y, Gamal N, Castaldi B. J Genet Eng Biotechnol. 2021 May 31;19(1):82. doi: 10.1186/s43141-021-00179-2. PMID: 34057580 Review.

• MicroRNA-520c-3p Modulates Doxorubicin-Chemosensitivity in HepG2 Cells. Ragheb MA, Soliman MH, Elzayat EM, Mohamed MS, El-Ekiaby N, Abdelaziz AI, Abdel-Wahab AA. Anticancer Agents Med Chem. 2021;21(2):237-245. Doi: 10.2174/1871520620666200502004817. PMID: 32357822

• MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma. Soliman MH, Ragheb MA, Elzayat EM, Mohamed MS, El-Ekiaby N, Abdelaziz AI, Abdel-Wahab AA. Anticancer Agents Med Chem. 2021;21(2):246-253. Doi: 10.2174/1871520620666200516145830. PMID: 32416702

• Simplified conservative surgery for placenta accreta spectrum (PAS): an abnormally invasive placenta (AIP) case. Mousa A, Elkhateb IT. BMJ Case Rep. 2021 Jan 11;14(1): e237960. Doi: 10.1136/bcr-2020-237960. PMID: 33431457

• A miRNA’s insight into the regenerating heart: a concise descriptive analysis. Afify AY. Heart Fail Rev. 2020 Nov;25(6):1047-1061. doi: 10.1007/s10741-019-09896-w. PMID: 31838633 Review.

• Competing Endogenous RNAs in Hepatocellular Carcinoma-The Pinnacle of Rivalry. Afify AY, Ibrahim SA, Aldamsisi MH, Zaghloul MS, El-Ekiaby N, Abdelaziz AI. Semin Liver Dis. 2019 Nov;39(4):463-475. Doi: 10.1055/s-0039-1688442. Epub 2019 Jun 26. PMID: 31242525 Review.

• Advanced genetic manipulation in lupus: capturing butterflies in an abandoned playground. Afify AY. Lupus. 2019 Oct;28(11):1378-1379. doi: 10.1177/0961203319871347. Epub 2019 Aug 29. PMID: 31466510

• The long non-coding road to endogenous cardiac regeneration. Afify ARY. Heart Fail Rev. 2019 Jul;24(4):587-600. doi: 10.1007/s10741-019-09782-5. PMID: 30900115 Review.

• Mesenchymal Stem Cell Therapy for Doxorubicin-Induced Cardiomyopathy: Potential Mechanisms, Governing Factors, and Implications of the Heart Stem Cell Debate. Abushouk AI, Salem AMA, Saad A, Afifi AM, Afify AY, Afify H, Salem HSE, Ghanem E, Abdel-Daim MM. Front Pharmacol. 2019 Jun 14; 10:635. Doi: 10.3389/fphar.2019.00635. eCollection 2019. PMID: 31258475 Free PMC article. Review.

• Epigallocatechin gallate (EGCG) and miR-548m reduce HCV entry through repression of CD81 receptor in HCV cell models. Mekky RY, El-Ekiaby N, El Sobky SA, Elemam NM, Youness RA, El-Sayed M, Hamza MT, Esmat G, Abdelaziz AI. Arch Virol. 2019 Jun;164(6):1587-1595. Doi: 10.1007/s00705-019-04232-x. Epub 2019 Apr 4. PMID: 30949812

• Pharmacological Manipulation of Trk, p75NTR, and NGF Balance Restores Memory Deficit in Global Ischemia/Reperfusion Model in Rats. Choucry AM, Al-Shorbagy MY, Attia AS, El-Abhar HS. J Mol Neurosci. 2019 May;68(1):78-90. doi: 10.1007/s12031-019-01284-1. Epub 2019 Mar 12. PMID: 30863991

• Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma. Waly AA, El-Ekiaby N, Assal RA, Abdelrahman MM, Hosny KA, El Tayebi HM, Esmat G, Breuhahn K, Abdelaziz AI. Front Physiol. 2019 Jan 24; 9:1918. doi: 10.3389/fphys.2018.01918. eCollection 2018.PMID: 30733684

• Destabilizing the interplay between miR-1275 and IGF2BPs by Tamarix articulata and quercetin in hepatocellular carcinoma. Shaalan YM, Handoussa H, Youness RA, Assal RA, El-Khatib AH, Linscheid MW, El Tayebi HM, Abdelaziz AI. Nat Prod Res. 2018 Sep;32(18):2217-2220. Doi: 10.1080/14786419.2017.1366478. Epub 2017 Aug 18. PMID: 28817968

• Correction to: Ectopic delivery of miR-200c diminishes hepatitis C virus infectivity through transcriptional and translational repression of Occludin. Elhelw DS, Riad SE, Shawer H, El-Ekiaby N, Salah A, Zekri A, Amleh A, Esmat G, Abdelaziz AI. Arch Virol. 2018 May;163(5):1405. doi: 10.1007/s00705-018-3798-6. PMID: 29572597

• Disruption of Claudin-1 Expression by miRNA-182 Alters the Susceptibility to Viral Infectivity in HCV Cell Models. Riad SE, Elhelw DS, Shawer H, El-Ekiaby N, Salah A, Zekri A, Esmat G, Amleh A, Abdelaziz AI. Front Genet. 2018 Mar 20; 9:93. Doi: 10.3389/fgene.2018.00093. eCollection 2018. PMID: 29616082

• Ectopic delivery of miR-200c diminishes hepatitis C virus infectivity through transcriptional and translational repression of Occludin. Elhelw DS, Riad SE, Shawer H, El-Ekiaby N, Salah A, Zekri A, Amleh A, Esmat G, Abdelaziz AI. Arch Virol. 2017 Nov;162(11):3283-3291. Doi: 10.1007/s00705-017-3449-3. Epub 2017 Jun 22. PMID: 28642978

• Unraveling the expression of microRNA-27a* & NKG2D in peripheral blood mononuclear cells and natural killer cells of pediatric systemic lupus erythematosus patients. Sourour SK, Aboelenein HR, Elemam NM, Abdelhamid AK, Salah S, Abdelaziz AI. Int J Rheum Dis. 2017 Sep;20(9):1237-1246. doi: 10.1111/1756-185X.13099. Epub 2017 May 19. PMID: 28523761

• A randomized multicenter study: safety and efficacy of mini-pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1-18 years with immune thrombocytopenia. Elalfy M, Reda M, Elghamry I, Elalfy O, Meabed M, El-Ekiaby N, El-Hawy MA, Goubran H, El-Ekiaby M. Transfusion. 2017 Dec;57(12):3019-3025. doi: 10.1111/trf.14301. Epub 2017 Sep 6. PMID: 28880361 Clinical Trial.

• MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients. Rahmoon MA, Youness RA, Gomaa AI, Hamza MT, Waked I, El Tayebi HM, Abdelaziz AI. Growth Factors. 2017 Jun;35(2-3):76-87. doi: 10.1080/08977194.2017.1354859. Epub 2017 Jul 27. PMID: 28747084

• Reduction of CD19 autoimmunity marker on B cells of paediatric SLE patients through repressing PU.1/TNF-α/BAFF axis pathway by miR-155. Aboelenein HR, Hamza MT, Marzouk H, Youness RA, Rahmoon M, Salah S, Abdelaziz AI. Growth Factors. 2017 Jun;35(2-3):49-60. doi: 10.1080/08977194.2017.1345900. Epub 2017 Jul 7. PMID: 28683581

• miR-29a Promotes Lipid Droplet and Triglyceride Formation in HCV Infection by Inducing Expression of SREBP-1c and CAV1. Mahdy MM, El-Ekiaby NM, Hashish RM, Salah RA, Hanafi RS, Azzazy HM, Abdelaziz AI. J Clin Transl Hepatol. 2016 Dec 28;4(4):293-299. doi: 10.14218/JCTH.2016.00046. Epub 2016 Dec 26. PMID: 28097097

• miR-34a: Multiple Opposing Targets and One Destiny in Hepatocellular Carcinoma. Yacoub RA, Fawzy IO, Assal RA, Hosny KA, Zekri AN, Esmat G, El Tayebi HM, Abdelaziz AI. J Clin Transl Hepatol. 2016 Dec 28;4(4):300-305. doi: 10.14218/JCTH.2016.00031. Epub 2016 Dec 27. PMID: 28097098

NGU- SOM, as an Egyptian university, aspires to lead in all aspects including community and environmental awareness,  while valuing the  importance of social responsibility as an integral part of medical education. 

The school has a number of bodies that serve the community and develop the environment. 

1- The Community Service and Environmental Development Affairs Committee implements and monitors plans.  

2- New Giza University Community Hospital, in Sayeda Nafeesa serves patients free of charge in the fields of pediatrics, internal medicine, surgery and rare diseases. 

3- Cooperation with the Crisis and Disaster Unit at the university 

4-The NGU students’ clubs that share in medical conveys: 

• Eight medical convoys were organized by the students’ clubs and with the participation of some members of the faculty.5-Awareness campaigns: 

Campaigns a provided by the school and are carried out by students under the supervision of faculty members and have included awareness campaigns on hepatitis, diabetes and maintaining food safety 

6- The Lancet Countdown Egypt Report has been launched from New Giza University and  works to ensure that health is at the center of government response to climate change.

7-COP27-ASRT call for “Climate Change Adaptation and Nature Conservation”:

A multidisciplinary team was formed by the School of Medicine, the School of Information Technology, and the School of Engineering at New Giza University. The team submitted a concept note for a research proposal entitled: “Integrating Artificial Intelligence and Energy Simulation to Enhance Sustainability Standards for Educational Buildings: A Case Study of Occupant-Based Policies at New Giza University”.  The team’s  research was selected as one of the projects for the implementation plan of COP27 

8-Misr ElKhair food distribution campaigns:

NGU students assist in that deliver the necessary materials to those in need. Including packing of Ramadan food boxes to be distributed to impoverished families.

ALUMNI OFFICE 

Vision 

Continued support and open channels of communication with SOM graduates, allowing them to thrive in local and international workforces.  

Mission  

Establishing and maintaining contact with SOM graduates after graduation allows the University to continuously aid them in further development of their skills and tailoring their abilities to the match the needs of the medical labor market. 

Graduation Ceremony Pictures 

Class of 2022 

Class of 2023 

The student support team serves the undergraduate student community through group and individual meetings.

Mission 

The team facilitates student-faculty interaction to provide the needed help and support in matters both academic and psychological.

Vision

The student support team is committed to achieving New Giza University’s vision to create a community of interdisciplinary researchers, professors, and students who foster excellence and encourage innovation.

The team serves this vision by encouraging students to learn how to ask for help, become more reflective and self-aware and to assume a proactive approach in the face of adversity.

Aim

Our aim is to offer outstanding, clear and accessible advice on various matters. We recognise that medical students are subject to all sorts of stressors and having difficulty at some point during their academic journey is only to be expected. Our experienced staff can easily provide the right help and support for them, no matter what the problem may be.

Introduction to forms of support on offer

 Regular support

For students who repeated the previous year or had to re-sit their summative exams

For students who get 50% or less in their midyear or cohort exams

 Intensive support

For students repeating their academic year.

 Revisiting part of the syllabus

For late admissions, transfer students and those who miss more than a few days of coursework with a valid and accepted excuse.

Psychological support

For students facing anxiety or depressive symptoms related to studying or examinations, family problems, peer problems or relational problems.

Responsible Faculty Roles & Responsibilities

• Student Academic Support Lead

Dr Omneya Kamel

• Student Academic Support Deputies

Dr Nancy Elghandour

Dr Mona Hafez

• Student Psychological Support Lead

Dr Maie Hilmy

• Student Psychological Support Deputies

Mental health team

Small Group Teaching Assistants

QAU MISSION   

        The role of the Quality Assurance Unit (QAU) is: to support a culture of total quality management across the School of Medicine at NGU; to ensure that standards and guidelines within the teaching, learning and assessment processes for NGU’s undergraduate medical program are implemented; ensure that good practice is recognized and rewarded, and that any deficiencies that impact on the delivery of a high-quality program are rapidly identified and managed.  

The systems and practices implemented by the unit aim to ensure the school works in partnership between staff and students to continually improve the educational program and learning environment. The unit targets the identification of good practices as well as deficiencies and obstacles. It works on: performance follow up; suggestions for development and enhancement; staff development; and the systematic review and development of processes, policies, strategies and priorities to support continuing improvement. The unit’s approach is aligned with the adopted quality assurance system of New Giza University and the National Authority for Quality Assurance and accreditation of higher education; aiming to fulfill the missions and vision of New Giza University and the School of Medicine.   

OBJECTIVES  

1- To promote awareness of quality principles and a quality culture throughout the school among staff and students.  

2- To develop a collective self-critical and self-reflective attitude amongst all staff that enables them to produce and act on self-assessment and subsequent action plans.  

3- To ensure that quality standards and guidelines are followed, to promote quality delivery, to detect and manage deficiencies, and to document and report quality assurance and improvement activities.  

4- To support the development processes and the continuous quality improvement of education effectiveness.  

5- To deliver the quality assurance functions that align with the University’s overarching QA vision and mission statements.   

6- To ensure the university is well prepared to produce evidence of quality management and improvement to relevant stakeholders  

Tuition Fees:

The School of Medicine tuition fees for the academic year (2024-2025): EGP 252,000 EGP +1,000 USD for Egyptian students. For more information, please click here.

Deadlines:

The deadline for the academic year 2024/2025 will be announced soon.

Fill out the online application form.

For more information about the application process and how to apply to the School of Medicine, please visit the Admissions section.